Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...

John Berdahl, MD, discusses a non-surgical, non-drug treatment for glaucoma approved by the FDA in 2024. The pump uses negative pressure to lower eye pressure by an average of 39% in clinical trials, ...

A new study suggests that adults over the age of 55 with too much "good" HDL cholesterol may be at a higher risk of ...

Among patients with suspected or confirmed glaucoma, higher average blood pressure and greater variability in blood pressure ...

The cholesterol that’s good for your heart health might be bad for your eye health, and vice versa, a new study says ...

"Good" (HDL) cholesterol, usually considered to be beneficial for health, may be linked to a heightened risk of the serious ...

Himani Goyal, MD, takes glaucoma care to the next level by embracing advancements that extend beyond traditional treatment ...

Good' (HDL) cholesterol, usually considered to be beneficial for health, may be linked to a heightened risk of the serious ...

Glaucoma is a complex group of eye diseases that lead to progressive dam- age to the optic nerve, often associated with increased intraocular pressure (IOP). It is one of the leading causes of ...

Qlaris Bio is seeing double when it comes to phase 2 wins for its eye drug, hitting the primary endpoints in trials that both spanned primary open angle glaucoma (POAG) and ocular hypertension (OHT).

Touting its novel approach for treating glaucoma, Qlaris Bio Inc. reported promising top-line data from two phase II studies testing QLS-111 in patients with primary open-angle glaucoma and ocular ...